As FDA faces higher-profile pressure on its opioid policies, the agency is sticking to its classic engagement strategy – emphasizing its faith in the scientific underpinning of its decisions.
During a March 13 hearing, several members of the Senate Health, Education, Labor and Pensions Committee pressed FDA Commissioner Margaret Hamburg to gain better control over